Pea protein drink may help Crohn's patients during Flare-Ups
NCT ID NCT07113431
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a dietary plan combining a special diet for inflammatory bowel disease (IBD-AID) with a pea protein drink (Kate Farms Peptide 1.5) in 20 adults experiencing a Crohn's disease flare and starting new immunologic therapy. The goal was to see if this approach improves nutrient intake and body composition compared to the diet alone. The study measured dietary recall and body composition using bioimpedance spectroscopy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pea protein plant-based oral nutrition supplement (Kate Farms Peptide 1.5) combined with a standardized IBD diet
- What this could lead to
- If successful, this dietary approach could help improve nutrition and body composition during Crohn's flares, potentially supporting better outcomes with new immunologic therapy.
- What could go wrong
- This is a small, completed trial with only 20 participants, so results may not apply broadly. The intervention is dietary and may not significantly alter disease course.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Aug 2023
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Moderate to severe CD as defined by physician and starting new biologic therapy * Able and willing to complete the study procedures * Age \> 18 * Able to comply with study measures in the opinion of the investigator Exclusion Criteria: * Diagnosis of short bowel syndrome * Presence of ileostomy or colostomy * Presence of a pacemaker or any electronic implantable device * Use of pre or probiotic supplements within 14 days of randomization * High risk for development of refeeding syndrome * In the opinion of the investigator would not complete the study procedures * Patients with active implanted medical devices, e.g. cardiac pacemakers, defibrillators or patients connected to electronic life support devices * Pregnant Patients: while the use of bioimpedance technology in pregnant patients has been shown to have no adverse effects, it has yet to be clinically validated for use with that population group * Serious, concomitant illness that, in the opinion of the investigator would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn'S disease(CD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States